CN Patent
CN107936005A — 一种依匹哌唑新晶型ii及其制备方法
Assigned to SHANGHAI SYNCORES TECHNOLOGIES Inc · Expires 2018-04-20 · 8y expired
What this patent protects
本发明涉及一种依匹哌唑新晶型及其制备方法。所述的依匹哌唑新晶型命名为晶型Ⅱ,使用Cu‑Kα辐射检测的X射线粉末衍射图谱中,在约5.2°,7.4°,9.8°,10.5°,14.3°,14.8°,18.6°,19.7°,23.6°(2θ)处有特征峰。本发明还提供一种制备依匹哌唑新晶型Ⅱ的方法,简便、重现性好,所得依匹哌唑新晶型Ⅱ纯度高、稳定性好,适于工业化生产。
USPTO Abstract
本发明涉及一种依匹哌唑新晶型及其制备方法。所述的依匹哌唑新晶型命名为晶型Ⅱ,使用Cu‑Kα辐射检测的X射线粉末衍射图谱中,在约5.2°,7.4°,9.8°,10.5°,14.3°,14.8°,18.6°,19.7°,23.6°(2θ)处有特征峰。本发明还提供一种制备依匹哌唑新晶型Ⅱ的方法,简便、重现性好,所得依匹哌唑新晶型Ⅱ纯度高、稳定性好,适于工业化生产。
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.